jm1c00159_si_001.csv (2.64 kB)
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer
dataset
posted on 2021-06-10, 19:15 authored by Kevin D. Freeman-Cook, Robert L. Hoffman, Douglas C. Behenna, Britton Boras, Jordan Carelli, Wade Diehl, Rose Ann Ferre, You-Ai He, Andrea Hui, Buwen Huang, Nanni Huser, Rhys Jones, Susan E. Kephart, John Lapek, Michele McTigue, Nichol Miller, Brion W. Murray, Asako Nagata, Lisa Nguyen, Sherry Niessen, Sacha Ninkovic, Inish O’Doherty, Martha A. Ornelas, James Solowiej, Scott C. Sutton, Khanh Tran, Elaine Tseng, Ravi Visswanathan, Meirong Xu, Luke Zehnder, Qin Zhang, Cathy Zhang, Stephen DannControl
of the cell cycle through selective pharmacological inhibition
of CDK4/6 has proven beneficial in the treatment of breast cancer.
Extending this level of control to additional cell cycle CDK isoforms
represents an opportunity to expand to additional tumor types and
potentially provide benefits to patients that develop tumors resistant
to selective CDK4/6 inhibitors. However, broad-spectrum CDK inhibitors
have a long history of failure due to safety concerns. In this approach,
we describe the use of structure-based drug design and Free–Wilson
analysis to optimize a series of CDK2/4/6 inhibitors. Further, we
detail the use of molecular dynamics simulations to provide insights
into the basis for selectivity against CDK9. Based on overall potency,
selectivity, and ADME profile, PF-06873600 (22) was identified
as a candidate for the treatment of cancer and advanced to phase 1
clinical trials.
